MAP2K7 and cancer: As two-drug regimens including inhibition of MEK or mTOR have demonstrated significant toxicities, assay development including optimal order of addition, peak levels and durations needed for effectively targeting these pathways in cancer cells will likely be needed to optimize the therapeutic index for patients.